
Monopar Therapeutics reports Q1 2026 loss, advances ALXN1840 NDA submission for Wilson disease.
Monopar Therapeutics announced a net loss of $3.9 million in Q1 2026, up from $2.6 million in Q1 2025, driven by increased R&D and administrative expenses. The company remains on track to submit its New Drug Application (NDA) for ALXN1840, a treatmen...


